Lantheus Hldg.

The U.S. FDA has approved TAUKLARIFY (florquinitau F 18) from Lantheus for positron emission tomography of the brain in adults to help assess Alzheimer-typical tau neurofibrillary tangles. The decision was based on two blinded studies with more than 500 subjects that showed high concordance in image readings; safety was evaluated in 1,734 subjects. Lantheus plans to support Alzheimer therapy programs through its Pharma Solutions business and is evaluating a path to broader commercial availability. » Mere på de.investing.com

CapVest-backed Curium will acquire Nasdaq-listed Lantheus for $102.50 per share in cash, plus non-transferable CVRs that could add up to $12.00 per share, bringing potential consideration to $114.50. The offer represents a roughly 38% premium to Lantheus' 60-day VWAP and has unanimous board approval. The combined group would operate across oncology, neurology and cardiology in more than 70 countries, integrating Curium's theranostics and manufacturing with Lantheus' US radiodiagnostics business. The transaction will be financed with debt and equity and is expected to close in the first half of 2027, subject to approvals. » Mere på finance.yahoo.com

Lantheus Holdings' stock rose to a 52-week high of $111.52 and is up roughly 39.7% year to date; market capitalization is about $7.25 billion. InvestingPro currently rates the stock as overvalued. The FDA issued a “Complete Response Letter” for the PET diagnostic kit LNTH-2501 due to manufacturing problems at a third‑party facility. Citizens and Mizuho have confirmed or raised price targets to $115 with positive assessments. Media reports say negotiations are underway over a possible sale to Curium, with an estimated offer of around $7 billion. » Mere på de.investing.com

The stock rose to $104.05, marking a 52-week high; market capitalization is about $6.77 billion. In Q1 2026 Lantheus beat expectations with adjusted EPS of $1.46 (expectation $1.23) and revenue of $377.3 million (expectation $354.87 million). The shares are up 59% over six months and 29.72% year-to-date. Lantheus says it is in talks about a possible sale to Curium with an estimated offer of around $7 billion; Mizuho raised its price target to $115 and its rating to "Outperform." » Mere på de.investing.com

According to Bloomberg, Lantheus Holdings is considering a possible sale after receiving an acquisition offer from Curium. The stock then rose by about 6% on Friday. » Mere på de.investing.com